Free Trial

TG Therapeutics (TGTX) News Today

TG Therapeutics logo
$64.26 +0.88 (+1.39%)
Closing price 11/10/2026 04:00 PM Eastern
Extended Trading
$64.66 +0.40 (+0.62%)
As of 05:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Why Is TG Therapeutics Up Today?

TG Therapeutics, Inc. (NASDAQ: TGTX) shares moved higher following strong third-quarter revenue growth and an increase in the company’s 2026 revenue outlook. Investors appear focused on continued demand for BRIUMVI, though earnings-per-share comparisons varied by analyst estimate.

  • Positive Sentiment: Third-quarter revenue increased 60.8% year over year to $259.9 million, topping the roughly $245.5 million analyst estimate. Earnings were $0.35 per share; that beat Zacks’ $0.28 estimate, though another reported consensus was $0.37. Zacks Q3 earnings article
  • Positive Sentiment: The company raised its 2026 global revenue outlook to $1 billion, above the roughly $961 million analyst consensus. Management attributed growth to BRIUMVI demand, making the higher target a key potential catalyst for the stock. Revenue outlook and dosing plans
  • Neutral Sentiment: TG Therapeutics plans simplified intravenous dosing around mid-2027 and a subcutaneous BRIUMVI launch in 2028. These could support future access and sales, but are longer-term opportunities that still depend on execution. CEO comments on revenue and BRIUMVI
Posted 9h agoAI Generated. May Contain Errors.

TG Therapeutics Latest News

Is Earnings Beat Altering The Investment Case For TG Therapeutics (TGTX)?
TG Therapeutics (NASDAQ:TGTX) Hits New 52-Week High - Time to Buy?
TG Therapeutics (TGTX) Q3 2026 Earnings Call Transcript
TG Therapeutics, Inc. (TGTX) Q3 2026 Earnings Call Transcript
What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call
TG Therapeutics beats Q3 2026 estimates on BRIUMVI momentum
TG Therapeutics (NASDAQ:TGTX) Posts Earnings Results
TG Therapeutics (TGTX) Stock Forecast & Price Target
TG Therapeutics (TGTX) Just Sparked A Bigger Question
TG Therapeutics Inc (TGTX)
TG Therapeutics (NASDAQ:TGTX) Director Sells 5,000 Shares

TG Therapeutics Media Mentions By Week

TG Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TGTX
News Sentiment
▼
0.50

0.58
▲
Average
Healthcare
News Sentiment

TG Therapeutics News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TGTX Articles
This Week
▼
26

5
▲
TGTX Articles
Average Week

TG Therapeutics Trends on MarketBeat

This week vs. last week
New Followers
2
+100%
Searches
1
-86%
Page Views
2,204
-44%
Get TG Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for TG Therapeutics dated 11/10/2026.
From Our Partners